Abstract
Modern approaches for treatments of channelopathies employ mutation-specific pharmacotherapies, use pharmacoagents alone, or a vast variety of ideas for genetic approaches, all with the purpose of restoring defective ion channels or attenuate their negative effects. An alternative to existing approaches is the use of synthetic channel-forming peptides (CFPs) with desirable selectivity, high ion transport rates and overall ability to supersede defective endogenous ion channels. Our synthetic CFPs represent derivatives of a peptide initially reconstituted from the second transmembrane segment of the α-subunit of Glycine receptor (M2GlyR), PARVGLGITTVLTMTTQSSGSRA.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
